At Montgomery McCracken, our collaborative approach connects clients with the right resources at the right time, fostering efficiency and delivering the outcomes our clients expect. We fully engage with client goals, providing strategic advice that supports informed decision-making and enables swift, decisive action, treating each client’s challenges as our own. Our clients include public and private companies, nonprofits, educational and governmental entities, and individuals across industries, whom we represent in complex litigation, intellectual property, bankruptcy, corporate law, and regulatory matters. With a strong presence in Pennsylvania, New York, New Jersey, and Delaware, we litigate across the U.S. and internationally. Founded over a century ago by esteemed Philadelphia lawyers, including U.S. Supreme Court Justice Owen J. Roberts, our legacy of excellence guides us as we continue to offer responsive, agile, and cost-effective legal solutions for our clients’ evolving needs.
On June 28, 2019, New Jersey Governor Phil Murphy stated that he
will sign the Jake Honig Compassionate Use Medical Cannabis Act
(A20) into law on July 2. If signed, this law would expand the
State of New Jersey's medical marijuana program. A20 would
create a new five-member Cannabis Regulatory Committee to oversee
the state's medical marijuana program. A20 also allows for
additional alternative treatment centers, which may provide
cultivation, manufacturing or dispensing, rather than all three,
which was previously required. A20 also phases out the state sales
tax on medical marijuana cutting it from 6.625 percent to 4 percent
on July 1, 2020, then to 2 percent on July 1, 2021.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
